What's Happening?
ImmunityBio, Inc., a biotechnology company, is facing a securities class action lawsuit following a warning from the FDA regarding misleading claims about its lead biologic product, Anktiva. The FDA flagged statements made by the company's executive chairman
and Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, which suggested that Anktiva could treat all cancers, despite being approved only for non-muscle invasive bladder cancer. These claims were made in a podcast and a TV ad, which the FDA determined to be false or misleading. As a result, ImmunityBio's stock price fell by over 21%, erasing nearly $2 billion from its market capitalization. The lawsuit, led by Hagens Berman, seeks to represent investors who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026.
Why It's Important?
The lawsuit against ImmunityBio highlights significant concerns about corporate accountability and the impact of misleading promotional practices on investors and public health. The FDA's warning underscores the importance of accurate and truthful communication in the pharmaceutical industry, particularly regarding the efficacy of treatments. The sharp decline in ImmunityBio's stock price reflects the financial risks associated with regulatory scrutiny and potential legal liabilities. This case could influence investor confidence and prompt stricter oversight of promotional activities in the biotech sector, affecting how companies communicate about their products.
What's Next?
The lead plaintiff deadline for the class action lawsuit is set for May 26, 2026. Investors who suffered losses are encouraged to submit their claims, and witnesses with relevant information are urged to contact Hagens Berman. The outcome of this lawsuit could lead to financial restitution for affected investors and potentially result in changes to ImmunityBio's promotional practices. Additionally, the case may prompt other biotech companies to reassess their marketing strategies to ensure compliance with FDA regulations and avoid similar legal challenges.
